Notably, combination strategies involving WNT pathway inhibitors in patients with BRAF-mt mCRC may be justified in the future by the observation of the association between WNT5A promoter methylation and BRAFV600E mutation in CRC patients.59 The gene discussed is BRAF; the disease is colorectal carcinoma.